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Abstract
Background: An enduring challenge in personalized medicine is to select right drug for individual patients. Testing
drugs on patients in large clinical trials is one way to assess their efficacy and toxicity, but it is impractical to test
hundreds of drugs currently under development. Therefore the preclinical prediction model is highly expected as it
enables prediction of drug response to hundreds of cell lines in parallel.
Methods: Recently, two large-scale pharmacogenomic studies screened multiple anticancer drugs on over 1000 cell
lines in an effort to elucidate the response mechanism of anticancer drugs. To this aim, we here used gene
expression features and drug sensitivity data in Cancer Cell Line Encyclopedia (CCLE) to build a predictor based on
Support Vector Machine (SVM) and a recursive feature selection tool. Robustness of our model was validated by
cross-validation and an independent dataset, the Cancer Genome Project (CGP).
Results: Our model achieved good cross validation performance for most drugs in the Cancer Cell Line
Encyclopedia (≥80 % accuracy for 10 drugs, ≥ 75 % accuracy for 19 drugs). Independent tests on eleven common
drugs between CCLE and CGP achieved satisfactory performance for three of them, i.e., AZD6244, Erlotinib and
PD-0325901, using expression levels of only twelve, six and seven genes, respectively.
Conclusions: These results suggest that drug response could be effectively predicted from genomic features. Our
model could be applied to predict drug response for some certain drugs and potentially play a complementary
role in personalized medicine.
Keywords: Drug sensitivity prediction, Feature selection, Recursive feature elimination
Background
Though having quite similar clinical symptoms, different
patients may have different responses to the same drug or
therapy. So personalized medicine, which makes medical
decisions based on patients’ genetic content, becomes the
main direction of the future medical science. In order to
develop and access targeted therapies for individuals, one
must resort to the lengthy and expensive process of drug
development and validation in clinical trials, the most
direct way to assess drug efficacy and toxicity. But the
scarcity of resources limited this scheme in practical ap-
plications. One possible solution to this problem is to
directly measure the sensitivity of a patient’s tumor cells to
a drug of interest in two/three-dimensional in-vitro cul-
tures [1] or in-vivo models such as mouse xenograft and
genetically engineered mouse models [2]. This approach
has the potential of capturing most of the relevant bio-
logical features of a patient’s tumor, and therefore provid-
ing better models to test drug sensitivity. However, such
an approach is costly, time consuming and hardly scalable
to screen dozens or hundreds of drugs in parallel.
With the development of the high-throughput technol-
ogy in the past few decades, an alternative scheme was
proposed by several research groups to build genomic pre-
dictors of drug response from large panels of cancer cell
lines [3–8]. Most of these methods are based on gene ex-
pression profile. For instance, Staunton et al. developed a
weighted voting classification model to predict anticancer
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drug sensitivity based on gene expression profile of NCI-
60 data [9]. Based on the same dataset, Riddick et al. built
an ensemble regression model using Random Forest [10];
Lee et al. developed a co-expression extrapolation algo-
rithm by comparing the differences of gene expression be-
tween sensitive and resistant cell lines [11]. Meanwhile,
other researchers focused on a specific type of cancer
owing to the diversity of different cancer types (Bio-
markers of a certain drugs for different cancers are differ-
ent). For example, Holleman et al. studied gene expression
patterns in drug-resistant leukemia cells, which showed
that the combination of resistant gene expression is closely
related to the risk of recurrence of disease [12]. In addition
to gene expression, some researchers explored the rela-
tionships between chemotherapy sensitivity and epigenetic
modifications. For example, Shen et al. used nucleotide se-
quences of methylation to predict drug response in cancer
cells via a series of methylation markers. Although many
biomarkers have been detected, these methods are still
limited by the relatively small sample size. In order to
further clarify the relationship between anticancer drug
sensitivity and genomic instability, researchers recently
collected a large genetic data set of more than 1000 hu-
man tumor cell lines and their pharmacological responses
of 24 and 138 anticancer drugs [3, 4]. They both applied
an elastic net model to predict anticancer drug sensitivity
based on genomic instability data including gene muta-
tion, variation of DNA transcription, and cancer-related
gene translocation.
However, from the practical perspective, patients may
care more about whether a drug will work for them or not
(sensitive or insensitive), rather than a specific value. In
such case, anticancer drug sensitivity prediction becomes
a binary classification problem instead of a regression
problem, where genetic annotations are served as features
and response indicator is the classification category. If
some gene signatures are detected to be responsible for
drug sensitivity, then one can resort some machine-
learning tools to characterize these signatures of a patient
based on high throughput profiling and predict its sensi-
tivity to a given drug. Towards this aim, we first classified
all cell lines in CCLE into three groups according to their
normalized drug response values (activity area). After
recursive feature selection and parameter optimization
through cross validation, an SVM model was built for each
drug in the CCLE dataset. 10-fold cross validation indi-
cated that 10 of 22 drugs performed satisfactory perform-
ance with model accuracy (the predictive performance of
the SVM model) more than 80 %. An independent test on
CGP showed that 3 of 11 common drugs between CCLE
and CGP achieved a good result in terms of IC50. This re-
sult reconfirmed the inconsistency of therapeutic response
for some drugs between these two data sets [13]. The gen-
eration of genomic predictor of drug response in the
preclinical setting as the model proposed in our study
could potentially accelerate the emergence of “personal-
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Anticancer drug sensitivity
In order to develop robust genomic predictor of re-
sponse to anticancer drugs, we collected, curated, and
annotated published data sets of two recent large-scale
preclinical studies, namely cancer cell line encyclopedia
(CCLE) [3] and the cancer genome project (CGP) [4].
CCLE
Consists of a large scale of genomic data, i.e., gene expres-
sion, mutation status and copy number alteration for 947
human cancer cell lines, as well as 8-point dose–response
curves for 24 chemical compounds across 479 cell lines.
We used the area under dose–response curves (termed as
activity area in [3]) to evaluate the sensitivity of drug to a
given cell line. Compared to the IC50 and EC50, activity
area could capture the efficacy and potency of a drug sim-
ultaneously. All cell lines in this dataset were cultured in
RPMI or DMEM with 10 % fetal bovine serum [15, 16].
CGP
The Cancer Genome Project used the human genome se-
quencing and high-throughput mutation detection tech-
niques to identify somatically acquired sequence variants/
mutations and hence identify genes critical to the develop-
ment of human cancers (a compilation of gene expression,
chromosomal copy number, and massively parallel se-
quencing data from 947 human cancer cell lines). Cell line
drug sensitivity was measured as the concentration at
which the drug inhibited 50 % of the cellular growth
(IC50) [4]. All cell lines were grown in RPMI or DMEM/
F12 medium supplemented with 5 % FBS and penicillin/
streptavidin, and maintained at 37 °C in a humidified at-
mosphere at 5 % CO2.
Drug response data used in this paper were publicly
available from the CCLE (www.broadinstitute.org/ccle/)
and CGP (www.cancerrxgene.org/) websites. Raw gene
expression profiles (Affymetrix CEL format) for CCLE
and CGP cell lines were freely retrieved from the CCLE
website and ArrayExpress under the accession number
E-MTAB-783, respectively.
Sample classification based on drug sensitivity
Drug sensitivity values (activity area in CCLE) were first
normalized to zero mean and unit variance across all
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treated cell lines. For each drug, cell lines with normal-
ized activity area at least 0.8 standard deviations (SDs)
above the mean were defined as sensitive to the com-
pound, whereas those with activity area at least 0.8 SDs
below the mean were defined as resistant. Cell lines with
activity area within 0.8 SDs of the mean were considered
to be intermediate and eliminated from our analysis [9].
Combining and homogenizing cell line between CCLE and
CGP
In order to combine the data generated by two separated
laboratories into a uniform model, we implemented an R
script ComBat [17] from the sva library to eliminate
batch effects between two expression data sets. Batch ef-
fects are subgroups of measurements that have qualita-
tively different behavior across conditions and are
unrelated to the biological or scientific variables in a
study. For example, batch effects may occur if a subset
of experiments was run on Monday and another set on
Tuesday, if two technicians were responsible for differ-
ent subsets of the experiments, or if two different lots of
reagents, chips or instruments were used. ComBat used
an empirical Bayes method to adjust potential batch ef-
fects between two data sets.
Feature selection by SVM-RFE, F-score and random forest
For many learning domains, a human defines the features
that are potentially useful. However, not all of these fea-
tures may be relevant. In such a case, choosing a subset of
the original features will often lead to a better perform-
ance. For supervised learning problems including drug
sensitivity prediction, feature selection algorithms choose
the optimal feature subset through maximizing a function
of predictive accuracy.
Three general classes of feature selection algorithms
are often used in the literature: filter methods, wrapper
methods and embedded methods. F-score is a typical fil-
ter method, which applies a statistical measure to assign
a scoring to each feature [18, 19]. Features are then
ranked by the score and either selected to be kept or re-
moved from the dataset. Given training vectors χκ, κ = 1,
…,m, if the number of positive and negative instances
are n+ and n−, respectively, then the F-score of the i-th
feature is explained as follows:
































are the average of the i-th feature of
the whole, positive, and negative data sets, respectively;
xk,i
(+) is the i-th feature of the k-th positive instance, and
xk,i
(+) is the i-th feature of the k-th negative instance. The
numerator shows the discrimination between the posi-
tive and negative sets, and the denominator defines the
one within each of the two sets. The larger the F-score
is, the more likely this feature is more discriminative. In
general, this kind of approaches is easy to implement
and computationally efficient, but the drawback is that it
considers the feature independently and thus neglects
the combination effects between different features.
In our study, features are selected using a recursive
feature selection namely SVM-RFE (Support Vector Ma-
chine Recursive Feature Elimination). SVM-RFE is a wrap-
per method by considering feature selection as a search
problem, where different combinations are evaluated and
compared to other combinations. In detail, it selects opti-
mal features from an initial feature set by the following
steps: i) fits a simple linear SVM, ii) ranks the features based
on their weights in SVM solution, iii) eliminates the feature
with the lowest weight to get the gene rank. Selected top
features were then used to fit an SVM model. In contrast to
filter-based models, SVM-RFE is computationally expensive,
but it is much possibly to find the best feature combination.
The Random Forest (RF) uses a collection of decision tree
classifiers, where each tree in the forest has been trained
using a bootstrap sample of individuals from the data, and
each split attribute in the tree is chosen from among a ran-
dom subset of attributes. RF is applicable to very high di-
mensional data with fewer observations and can handle the
problems of noisy data and imbalanced classes [20].
Support vector machine
Support vector machine (SVM) is a supervised learning
algorithm that analyzes data and recognizes patterns,
used for classification and regression analysis. Basically,
the SVM model will represent samples as points in the
feature space, such that samples of two categories are di-
vided by a clear gap as wide as possible. New samples
are then mapped into the same space and predicted to a
category based on which side they fall on.
In addition to linear classification, SVMs can also effi-
ciently perform non-linear classifications using a so-called
kernel trick, which implicitly maps the inputs into a higher
dimensional feature space. The kernel formulation has two
advantages. First, it reduces the number of model parame-
ters to match the number of samples (training cell lines)
and not the number of features. Second, it captures nonlin-
ear relationship between genomic and epigenomic features,
and cell-line drug sensitivities. In this study, SVM was im-
plemented by the R package e1071, where parameters are
optimized by a grid search over provided parameter ranges.
Model based testing
The best number of features and parameters (C and γ)
were obtained by minimizing the classification error of
SVM based on 10 iterations of 10-fold cross-validation.
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Different from CCLE, drug sensitivity in CGP was mea-
sured by IC50 rather than activity area, so the model
trained from CCLE is not applicable to CGP directly. But
there is a natural relation between activity area and IC50,
i.e., high activity area corresponds to low IC50 as shown in
Additional file 1. So we used IC50 to classify samples in
CGP, while leaving model trained by CCLE to validate this
model. For CGP dataset, sample classification is quite
similar to that in CCLE, i.e., IC50 values for each com-
pound were normalized to zero mean and unit variance.
Then, cell lines with IC50 at least 0.8 SDs above the mean
were defined as resistant, whereas those at least 0.8 SDs
below the mean were defined as sensitive. The rest inter-
mediate part is eliminated from our analysis.
When building the model, we selected the optimal pa-
rameters by a grid search in the range of cost: {0.1,1,10,
100,200,300,500,700,800,1000}, and gamma: {0.1,0.5,1,2,3,
4,5,6,7,8}. Next, we evaluated our algorithm by predicting
drug responses for an independent dataset CGP using the
model trained from CCLE. Finally, t-test and ROC curve
were explored to assess the robustness of our model.
Results
Computational framework
The conceptual framework of our study is shown in
Fig. 1. In the first step, cell lines in CCLE were divided
into three groups (Sensitive, Resistant and Intermediate)
according to their normalized sensitivities to a given
drug (see Fig. 2 as an example). Samples in sensitive and
resistant groups are retained to train an SVM model.
After this step, 2 drugs (L-685458 and Nilotinib) ended
up with very few valid samples due to the bias of their
drug sensitivity distributions, thus were discarded from
our further analysis. As is expected, samples in sensitive
and resistant groups are shown to have very distinct
gene expression patterns (an example in Fig. 3). Next,
we used gene expression features selected by SVM-RFE
to build an SVM model for the CCLE dataset, where the
optimal feature number and parameters were obtained
by 10-fold cross validation.
As an independent dataset, CGP, was used to further
evaluate our method based on the model built from
CCLE. Since gene expression profiles of two data sets
are conducted by two different platforms and thus have
significantly different magnitudes (Fig. 4a), we first re-
moved the batch effects using the ComBat function in R
(Fig. 4b). Then standardized gene expression profile in
CGP was fed to the model built from CCLE to get the
attribute (sensitive or resistant) of each cell line. The
final result of CGP was got by comparing the predictions
with the truth by sample classification based on their
IC50 values (details are in the Method part).
Fig. 1 Computational framework. In the left panel, cell lines in CCLE were first divided into three groups according to their normalized drug
response values. Then gene expression features were selected by SVM-RFE for building an SVM model, where the optimal feature number and
parameters were obtained by a 10-fold cross validation. To test the generalization ability of the model, in the right panel, gene expression profile
of CGP data set was fed to the model to get the attribute (sensitive or resistant) of each cell line. Then CGP performance was measured by
comparing the model prediction with the sample classification based on the normalized IC50









































































Fig. 3 Gene expression of sensitive and resistant cell lines for Panobinostat
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Cross validation in CCLE and analysis of selected features
cross validation in CCLE
Our model has three free parameters, i.e., the number of
selected top features and two model parameters (C and γ)
in SVM. Here, a 10-fold cross validation on CCLE dataset
is conducted to get the optimal gene features and parame-
ters. Examination on prediction accuracies with respect to































































































































































Fig. 4 Elimination of Batch effect by ComBat. Boxplot showing gene expression distributions before (a) and after (b) ComBat for five cell lines in
CCLE and CGP
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increasing first and decreasing afterwards with the in-
crease of selected features (see four examples in Fig. 5).
We concluded that, for all drugs tested, only a few genes
could be enough to enable a satisfactory accuracy. The op-
timal gene numbers and parameters for drugs in CCLE
are listed in Additional file 2.
Next, an SVM model was built for each drug after get-
ting the optimal features and model parameters conducted
by 10-fold cross validation (Fig. 6). By 10-fold cross valid-
ation, accuracies of our model are around 80 % for most
drugs in CCLE, and the highest accuracy of 91.73 % was
attained for a pathway targeted compound, the topoisom-
erase 1 inhibitor Irinotecan. The kind of phenomenon was
also reported by Jang et al., who showed that pathway tar-
geted compounds lead to more accurate predictors than
classical broadly cytotoxic chemotherapies [21]. Perform-
ance of two MEK inhibitors (AZD6244, PD-0325901) was
also quite promising with the model accuracies of 85.44 %
and 85.78 %, respectively. Accuracies for four EGFR
inhibitors are 76.3 %, 86.67 %, 79.77 % and 76.17 %, re-
spectively. The lowest accuracy of 69.35 % was obtained
for LBW242, which is also the worst prediction in the
CCLE paper [22], implying the consistence of our result
with the Elastic net model.
To further emphasize the fact that drug response can
be predicted from genomic features, we clustered all cell
lines in CCLE dataset based on their baseline gene ex-
pressions (Additional file 3). Then examined whether
there are significant differences between these clusters in
terms of copy number variant or mutation status. Re-
sults indicate that there are significant differences in
copy number and mutation status between different
clustering categories (Additional file 4).
Selected features are associated with tumorigenesis or
drug response
Selected genes for CCLE drugs are shown in Additional
file 2 and their functions in tumorigenesis are listed in
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Fig. 5 Prediction accuracy and number of selected features for four drugs. Prediction accuracies at different numbers of selected top features for
four drugs, i.e., AZD6244, Erlotinib, Sorafenib and AZD0530. The optimal feature numbers are highlighted in red
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Additional file 5. It is shown that many selected genes
are reported to have close relationship with tumorigen-
esis or cancer progression. For example, the selected top
features for AZD6244 are SPRY2, FAM127B, GDF15,
CAST, DAB2, CLEC11A, PRRG1, EDN1, CCL20, AXL,
PPAP2C and ITGA4. Among them, SPRY2 is reported
to have a consistent repressive expression in malignant
hepatocytes compared with normal or cirrhotic hepa-
tocytes in human hepatocellular carcinoma where the
MAPK activity is enhanced via multiple hepatocarcino-
genic factors [23]. GDF15 was also reported as an epi-
genetic biomarker for detection of bladder cancer from
DNA-Based analyses of Urine samples [24]. In a recent
study of microarray-based methylated-CpG island recov-
ery assay, hypermethylation and low expression level of
ITGA4 were reported to be enriched in breast cancers
[25]. Direct bisulfite sequencing also showed widespread
methylation occurring in intragenic regions of the WT1,
PAX6 and ITGA4 genes and in the promoter region of
the OTX2 gene in breast cancer tissues [25].
In order to test the effectiveness of SVM-RFE, feature
selection was also conducted by F-score [18, 19] and
random forest [26–28]. Results indicate that model
based on SVM-RFE (≥80 % accuracy for 10 drugs, ≥
75 % accuracy for 19 drugs) achieves much better per-
formance than F-score (≥80 % accuracy for 1 drugs, ≥
75 % accuracy for 5 drugs) for all drugs and random forest
(≥80 % accuracy for 8 drugs, ≥ 75 % accuracy for 10 drugs,
Additional file 6). Furthermore, random forest was used to
predict drug sensitivity (CGP IC50). Results reveal that
SVM prediction model achieves better performance for
some drugs (Erlotinib, Paclitaxel and PF-2341066 etc.)
than random forest model (Detailed results in Additional
files 7, 8, 9, 10).
Independent validation in CGP
Next, we further validated our algorithm by an inde-
pendent dataset CGP based on the model trained from
CCLE. Since CCLE and CGP were generated by two dif-
ferent consortiums and platforms, the total numbers of
genes and expression distributions are significantly dif-
ferent between these two data sets. To make sure a uni-
form data distribution, the ComBat function from the
sva package in R is applied to these two data sets to re-
move the batch effect.
Performances of 11 common drugs between CCLE
and CGP are shown in Additional file 2. As is shown, 3
of these 11 drugs (AZD6244, Erlotinib and PD-0325901)
achieve a relatively good performance of AUC from 0.57
to 0.7 (Fig. 7), but the rest eight drugs only give the
AUC values around 0.5 (Additional files 11 and 12). Pre-
dicted drug responses of sensitive and resistant samples
are significantly different for AZD6244 (Fig. 7a, p-value
= 3.316e-12 by t.test), PD-0325901 (p-value = 5.851e-14)
and Erlotinib (p-value = 1.885e-2).
In addition, we also built an SVM model for each drug
in CGP using IC50 as drug response measurement ac-


















































































































Fig. 6 Cross validation results for CCLE drugs. For each drug in CCLE, model accuracy was obtained through a 10-fold cross validation. Barplot
shows accuracy values for all drugs in CCLE
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list according to their importance (termed as “CGP_Impor”)
in drug sensitivity prediction (Additional file 13). In order
to test the consistency of this list with that by CCLE
(termed as “CCLE_Impor”), we split these two lists (top
1500 genes) into 3 groups and examined their overlaps in
each group (Table 1). Results by Fisher’s exact test indicate
that the overlap between CGP_Impor and CCLE_Impor
are significantly.
Discussion and Conclusions
The generation of genetic predictions of drug response
in the preclinical setting and their incorporation into
cancer clinical trial design could speed the emergence of
“personalized” therapeutic regimens. In our study, a ro-
bust predictor was built for this purpose using an SVM
model after recursive feature selection. 10-fold cross val-
idation on CCLE data set showed that our model
achieves the accuracy of over 80 % for 10 of 22 drugs.
Independent test on CGP suggests that only 3 of 11
common drugs between CCLE and CGP get satisfying
result, further implying the inconsistency between these
two data sets. The novelty of our algorithm lies on the
following aspects. First, most previous work on drug re-
sponse prediction mainly based on individual dataset,
such as NCI60, CCLE or CGP, but seldom see integra-
tion analysis. We combined datasets generated by two
important studies and further checked their consistency
in drug response profiles. Second, a backward feature se-
lection approach based on linear-kernel SVM was used
to selected drug response-relevant features instead of a
screening scheme by CCLE and CGP. So combination
effects of features could be possibly captured by our
model compared to filter methods such as F-score. Fi-
nally, we transformed the original regression problem
into a classification problem by a discretization strategy,
thus more machine-learning tools could be incorporated
to this problem.
Since mutation and copy number variation informa-
tion are also important indicators for drug response and
available in CCLE and CGP studies, we further investi-
gated whether a joint model by integrating these infor-
mation could possibly improve drug response prediction.
So we combined gene expression, copy number and













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 7 Independent tests on CCLE model for AZD6244, Erlotinib and PD-0325901. Boxplot and ROC curve (the bottom curve indicates drug
response, measured as the area over the dose–response curve, i.e., activity area) have been built to evaluate the svm model. (a) For drug
AZD6244, p-value by t test is 3.316e-12 and area under the curve is 0.668. (b) For drug Erlotinib, p-value by T test is 0.01885 and area under the
curve is 0.57. (c) For drug PD-0325901, p-value by t test is 5.851e-14 and area under the curve is 0.70
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conducted SVM-RFE for feature selection based on the
integrated dataset. Comparative results showed that the
integrated model achieved only slightly higher prediction
accuracies for most drugs in CCLE (Additional files 2
and 14), indicating the central role of gene expression in
drug response prediction. Similar phenomenon was also
observed in a recent comparison study by Costello et al.,
who concluded that gene expression data provides the
most predictive power for any individual profiling data
set [29]. So for the sake of generalization capability of
our model, it is much practical to use only gene expres-
sion to construct prediction model rather than all gen-
omic features.
However, our model also suffered from the following
limitations that can be addressed in our future work. First,
besides gene expression, epigenetic and protein level infor-
mation also play very important roles in drug response
mechanism, and thus should be incorporated in the pre-
diction model. Second, in our model, expressions of differ-
ent genes are assumed to be independent with each other,
but it is not the truth since functionally related genes
could form a pathway or molecular complex to execute a
specific biological process. So further attention should be
paid on taking these functional structures into consider-
ation for a better prediction of drug response.
Additional files
Additional file 1: Relationships between activity area and IC50 of
drug AEW541. For drug AEW541, a scatterplot was drawn to reveal the
relationship between activity area and IC50 with a p-value by spearman
correlation.
Additional file 2: Relevant information of CCLE drugs. In this study,
we analyzed 22 drugs in CCLE, here we listed the relevant information of
these drugs including model results and selected features that derive
from different data sets (EXP vs EXP + CPV + SNP). Also, feature selection
was conducted by F-score and random forest, then selected features
were used to build SVM model (Relevant information can be seen here).
Additional file 3: Results of Consensus Cluster in gene expression
dataset. All cell lines in CCLE dataset were clustered based on their
baseline gene expression. (A) Results when gene expression dataset were
divided into four categories. (B, C) In the process of Consensus cluster,
relative change in area under CDF curve tend to be stable when k = 4.
Then this value provides us with a basis for classification.
Additional file 4: Results of p.values returned from t.test and
Fisher’s exact test. To further emphasize the fact that drug response
can be predicted from genomic features, all cell lines in CCLE dataset
were clustered based on their baseline gene expression. Then t.test and
Fisher’s exact test are used to examine whether there are significant
differences between these clusters in terms of copy number variant and
mutation status, respectively. Results indicate that differences do exist
between different categories of cpv and snp data sets.
Additional file 5: Relationships between selected features and
cancer. For drug AZD6244, Erlotinib and PD-0325901, functions of
selected genes in tumorigenesis are listed here. Many selected genes are
reported to have close relationship with tumorigenesis or cancer progression.
(A) Relationships between selected features and cancer for drug AZD6244.
(B) Relationships between selected features and cancer for drug Erlotinib.
(C) Relationships between selected features and cancer for drug PD-0325901.
Additional file 6: Results of cross validation based on different
feature selection methods (SVM-RFE, F.score and Random Forest).
Feature selection was also performed by means of F.score and Random
Forest in order to demonstrate the efficiency of SVM-RFE. Then the
selected features were used to build the SVM model. Also, 10-fold cross
validation was conducted to test the robustness of the model. Comparison
of the model accuracy showed that features returned from SVM-RFE have
better generalization ability.
Additional file 7: Independent tests for AZD0530, AZD6244 and
Erlotinib in random forest predicting model. Boxplot and ROC curve
(the bottom curve indicates drug response, measured as the area over
the dose–response curve, i.e., activity area) have been built to evaluate
the model. (A) For drug AZD0530, p-value by t test is 1.609e-4 and area
under the curve is 0.626. (B) For drug AZD6244, p-value by t test is
3.45e-13 and area under the curve is 0.715. (C) For drug Erlotinib, p-value
by t test is 0.42882 and area under the curve is 0.526.
Additional file 8: Independent tests for Lapatinib, Nutlin-3 and
PD-0325901 in random forest predicting model. Boxplot and ROC
curve (the bottom curve indicates drug response, measured as the area
over the dose–response curve, i.e., activity area) have been built to
evaluate the model. (A) For drug Lapatinib, p-value by t test is 2.864e-4
and area under the curve is 0.619. (B) For drug Nutlin-3, p-value by t test
is 0.04791 and area under the curve is 0.636. (C) For drug PD-0325901,
p-value by t test is 2.2e-16 and area under the curve is 0.773.
Additional file 9: Independent tests for PD-0332991, PF-2341066
and PHA-665752 in random forest predicting model. Boxplot and
ROC curve (the bottom curve indicates drug response, measured as the
area over the dose–response curve, i.e., activity area) have been built to
evaluate the model. (A) For drug PD-0332991, p-value by t test is 0.6806
Table 1 Overlap between selected top features from CCLE and
CGP. For each drug, the table shows the number of common
genes between CCLE_Impor and CGP_Impor and overlapping
significance by Fisher’s exact test
Drug 1-500 p-value 501-1000 p-value 1001-1500 p-value
AZD6244 79 3.716 49 3.277 30 3.48
e-25 e-8 e-2
Erlotinib 79 3.716 47 2.225 38 3.47
e-25 e-7 e-4
PHA665752 72 1.603 40 8.163 33 7.76
e-20 e-5 e-3
AZD0530 72 1.603 42 1.722 32 1.32
e-20 e-5 e-2
Paclitaxel 74 8.309 45 1.368 39 1.71
e-22 e-6 e-4
PF-2341066 80 7.541 41 3.801 28 8.06
e-26 e-5 e-2
Sorafenib 79 3.716 31 2.177 22 0.46
e-25 e-2
PD-0325901 78 1.80 54 1.803 28 8.06
e-24 e-10 e-2
Lapatinib 68 4.78 46 5.586 33 7.76
e-18 e-7 e-3
PLX4720 78 1.80 41 3.801 29 5.38
e-24 e-5 e-2
PD-0332991 68 4.78 39 1.706 28 8.06
e-18 e-4 e-2
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and area under the curve is 0.539. (B) For drug PF-2341066, p-value by t
test is 0.1792 and area under the curve is 0.506. (C) For drug PHA-665752,
p-value by t test is 4.231e-3 and area under the curve is 0.391.
Additional file 10: Independent tests for PLX4720, Paclitaxel and
Sorafenib in random forest predicting model. Boxplot and ROC curve
(the bottom curve indicates drug response, measured as the area over
the dose–response curve, i.e., activity area) have been built to evaluate
the model. (A) For drug PLX4720, p-value by t test is 1.429e-7 and area
under the curve is 0.609. (B) For drug Paclitaxel, p-value by t test is 0.5993
and area under the curve is 0.482. (C) For drug Sorafenib, p-value by
t test is 0.9058 and area under the curve is 0.488.
Additional file 11: Independent tests on CCLE model for
PHA-665752, AZD0530, Paclitaxel and Sorafenib. The above graph
(boxplot, roc curve) shows the performance of 4 drugs—PHA-665752,
AZD0530, Paclitaxel and Sorafenib.
Additional file 12: Independent tests on CCLE model for PD-
0332991, PLX4720, Lapatinib, and PF-2341066. The above graph
(boxplot, roc curve) shows the performance of 4 drugs—PD-0332991,
PLX4720, Lapatinib and PF-2341066.
Additional file 13: Independent tests on CGP model for AZD6244,
Erlotinib, PD-0325901. CGP IC50 data was used to build svm model,
and then CCLE activity area data was used to test the model. Boxplot
and ROC curve have been built to evaluate the svm model. For drug
AZD6244, p-value by t test is 7.717e-4 and area under the curve is 0.621.
For drug Erlotinib, p-value by t test is 0.03194 and area under the curve is
0.555. For drug PD-0325901, p-value by t test is 1.487e-10 and area under
the curve is 0.678.
Additional file 14: Results of cross validation between different
data sets (EXP vs EXP + CPV + SNP). Gene expression, copy number
and gene mutation data sets were combined into an integrated data
sets. Then this integrated data sets was used to conduct SVM-RFE and
feature selection. Consequently selected features were used to build SVM
model. For each drug in CCLE, 10-fold cross validation was performed to
test the robustness of the model. Comparison of cross validation results
between different data sets (EXP vs EXP + CPV + SNP) can be seen in this
barplot.
Abbreviations
CCLE: The cancer cell line encyclopedia; CGP: The cancer genome project;
SVM: Support vector machine; RFE: Recursive feature selection; CCLE_Impor:
The gene rank list according to their importance in drug sensitivity prediction
when SVM model was built in CCLE using activity area as drug response
measurement; CGP_Impor: The gene rank list according to their importance in
drug sensitivity prediction when SVM model was built in CGP using IC50 as
drug response measurement.
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